Pharmaceutical wholesaler Lexon (UK) has filed an appeal against a £1,220,383 fine imposed by the Competition and Markets Authority for allegedly exchanging commercially sensitive information about prices for nortriptyline tablets.

In a decision made in March, the CMA found that between 2015 and 2017, King, Lexon (UK) and Alissa Healthcare Research exchanged commercially sensitive information about prices for nortriptyline tablets, the volumes they were supplying and Alissa’s plans to enter the market.

King was fined £75,573 and Alissa £174,912, with both companies handed reduced fines for admitting the infringement. Lexon did not admit to the infringement, and the CMA imposed a £1,220,383 fine.

An appeal has been filed in the Competition Appeal Tribunal against the CMA’s findings in the infringement decision and the penalty imposed. The CMA has said it will defend the appeal.